Anne Borgman's most recent trade in Nextcure Inc was a trade of 18,700 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nextcure Inc | Anne Borgman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 18,700 | 18,700 | - | - | Stock Option (Right to Buy) | |
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 53,125 | 21,875 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 53,125 | 106,223 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.07 per share. | 01 May 2025 | 24,709 | 97,452 (0%) | 0% | 1.1 | 26,439 | Common Stock |
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 15,938 | 17,812 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 15,938 | 122,161 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 37,500 | 61,874 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 37,500 | 75,000 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.59 per share. | 28 Feb 2025 | 15,405 | 46,469 (0%) | 0% | 1.6 | 24,494 | Common Stock |
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 11,250 | 33,750 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 11,250 | 57,719 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.59 per share. | 28 Feb 2025 | 4,621 | 53,098 (0%) | 0% | 1.6 | 7,347 | Common Stock |
| Nextcure Inc | Anne Borgman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 18,700 | 18,700 | - | - | Stock Option (Right to Buy) | |
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | 05 Mar 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy Common Stock) | ||
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | 05 Mar 2024 | 45,000 | 45,000 | - | - | Restricted Stock Units (RSUs) | ||
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | 29 Feb 2024 | 37,500 | 37,500 (0%) | 0% | 0 | Common Stock | ||
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | 29 Feb 2024 | 37,500 | 112,500 | - | - | Restricted Stock Unit (RSU) | ||
| Sutro Biopharma Inc | Anne Borgman | CHIEF MEDICAL OFFICER | 29 Feb 2024 | 13,126 | 24,374 (0%) | 0% | 4.9 | 64,449 | Common Stock | |
| Sutro Biopharma Inc | Anne Borgman | Chief Medical Officer | 15 Mar 2023 | 175,000 | 175,000 | - | - | Stock Option (right to buy Common Stock) | ||
| Sutro Biopharma Inc | Anne Borgman | Chief Medical Officer | 15 Mar 2023 | 150,000 | 150,000 | - | - | Restricted Stock Unit (RSU) | ||
| Nextcure Inc | Anne Borgman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 28,500 | 28,500 | - | - | Stock Option (Right to Buy) | |
| Nextcure Inc | Anne Borgman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 10,384 | 10,384 | - | - | Stock Option (Right to Buy) |